<DOC>
	<DOCNO>NCT00862121</DOCNO>
	<brief_summary>The purpose trial demonstrate Pentasa administer 2 g morning dose 4 g even dose efficacious active mild moderate CD .</brief_summary>
	<brief_title>A Study With Pentasa Patients With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Inclusion Criteria ( main ) : Age : least 18 year CD symptoms/onset disease : ≥ 3 month prior Visit 1 Ileal , ileocolonic colonic nonstricturing/nonpenetrating disease A confirmed location CD ( MRI , Xray ( small bowel and/or colon ) , and/or endoscopy ) A HarveyBradshaw score 5 12 Males nonpregnant , nonnursing woman Mild moderate active CD , define CDAI score 180 350 Active inflammatory disease ( CReactive Protein ( CRP ) level equal 5 mg/L ) , biopsy verified inflammation , fecal calprotectin level equal 50 µg/g ) Estimated creatinine clearance 75 ml/min Exclusion Criteria ( main ) : Any significant disease disorder , opinion Investigator , may either put patient risk participation trial , may influence result trial patient 's ability participate trial CD locate upper gastrointestinal tract and/or jejunal part small intestine , and/or colon leave colon flexure and/or isolate proctitis and/or anal disease Prior treatment resistance Pentasa ( mesalazine ) Chronic , dominant arthralgia rheumatoid arthritis Palpable abdominal mass Biologics ( eg antiTNFα ) must use trial 6 month Visit 1 Continuous usage systemic steroid ( exclude budesonide ) 3 month within past year Positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>